Javier Gállego
About
Javier Gállego is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Javier Gállego has authored 131 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 62 papers in Pulmonary and Respiratory Medicine and 36 papers in Surgery. Recurrent topics in Javier Gállego's work include Colorectal Cancer Treatments and Studies (60 papers), Gastric Cancer Management and Outcomes (39 papers) and Pancreatic and Hepatic Oncology Research (27 papers). Javier Gállego is often cited by papers focused on Colorectal Cancer Treatments and Studies (60 papers), Gastric Cancer Management and Outcomes (39 papers) and Pancreatic and Hepatic Oncology Research (27 papers). Javier Gállego collaborates with scholars based in Spain, United States and Belgium. Javier Gállego's co-authors include Alfredo Carrato, Carmen Guillén‐Ponce, Fernando Rivera, Manuel Benavides, Carles Pericay, Enrique Aranda, Joan Maurel, Eduardo Díaz‐Rubio, Ruth Vera and Encarnación González‐Flores and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
Javier Gállego
122 papers receiving 1.3k citations
Peers
Javier Gállego
Olivier Dubreuil France
Natsuko Okita Japan
Takeru Wakatsuki Japan
Lorenzo Antonuzzo Italy
Usha Malhotra United States
Hironaga Satake Japan
Boudewijn van Etten Netherlands
Tomomichi Kiyomatsu Japan
Hirokazu Shoji Japan
G. Des Guetz France
Citations per year, relative to Javier Gállego Javier Gállego (= 1×)
peers
Olivier Dubreuil
Countries citing papers authored by Javier Gállego
Since
Specialization
Citations
This map shows the geographic impact of Javier Gállego's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Gállego with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Gállego more than expected).
Fields of papers citing papers by Javier Gállego
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Javier Gállego. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Gállego. The network helps show where Javier Gállego may publish in the future.
Co-authorship network of co-authors of Javier Gállego
This figure shows the co-authorship network connecting the top 25 collaborators of Javier Gállego. A scholar is included among the top collaborators of Javier Gállego based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Gállego. Javier Gállego is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Adeva, Jorge, et al.. (2025). SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). Clinical & Translational Oncology. 27(8). 3293–3306.
2.
Hussein, Maen, Gazala Khan, Sreenivasa R Chandana, et al.. (2024). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.. Journal of Clinical Oncology. 42(16_suppl). 4136–4136.
3.
Pacheco-Barcía, Vilma, Alberto Carmona‐Bayonas, Javier Gállego, et al.. (2024). Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results.. Journal of Clinical Oncology. 42(3_suppl). 623–623.
4.
Riveiro‐Barciela, Mar, Sabela Carballal, Álvaro Díaz‐González, et al.. (2024). Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU. Gastroenterología y Hepatología. 47(4). 401–432.
5.
Lordick, Florian, Manish A. Shah, Kohei Shitara, et al.. (2023). 134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Annals of Oncology. 34. S1524–S1524.
6.
Alonso-Orduña, Vicente, Jaime Feliú, Ana Fernández Montés, et al.. (2023). 605P First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort. Annals of Oncology. 34. S435–S435.
7.
Viúdez, A., Emilia Alors‐Pérez, Saioa Goñi, et al.. (2022). Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Cancers. 14(23). 5993–5993.
8.
Garrido, Pedro, Paula Jiménez‐Fonseca, Eva Martínez de Castro, et al.. (2022). Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry. Biomedicines. 10(1). 148–148.
9.
Vidal, Joana, David Casadevall, Beatríz Bellosillo, et al.. (2021). Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial. Clinical Cancer Research. 27(10). 2890–2898.
10.
Ventero, María Paz, José Antonio Encinar, Pilar García-Morales, et al.. (2020). Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. Cancers. 12(12). 3717–3717.
11.
Salvia, Anna La, Jaume Capdevila, Marta Benavent, et al.. (2020). 1159MO Survival and prognostic factors analysis of 535 grade 3 gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN): Data from the Spanish Taskforce of Neuroendocrine Tumours Registry (R-GETNE). Annals of Oncology. 31. S772–S772.
12.
Taı̈eb, Julien, Fernando Rivera, Salvatore Siena, et al.. (2017). Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. Journal of Cancer Research and Clinical Oncology. 144(2). 321–335.
13.
Benavides, Manuel, et al.. (2017). PANOVA-2: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma – Updated efficacy results. Annals of Oncology. 28. iii72–iii73.
14.
Alonso, Vicente, Javier Gállego, José Ramón Rodríguez, et al.. (2016). Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02. Annals of Oncology. 27. vi178–vi178.
15.
Rivera, Fernando, Meinolf Karthaus, Manuel Valladares‐Ayerbes, et al.. (2016). PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials. Annals of Oncology. 27. ii114–ii114.
16.
Gállego, Javier, et al.. (2015). Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surgery. 15(1). 66–66.
17.
Custodio, Ana, Juan Moreno‐Rubio, Jorge Aparicio, et al.. (2014). Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy. Molecular Cancer Therapeutics. 13(9). 2226–2237.
18.
Gállego, Javier, Carmen Guillén‐Ponce, Adela Castillejo, et al.. (2010). Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. Clinical & Translational Oncology. 12(2). 142–147.
19.
García‐Carbonero, Rocio, Vicente Alonso Orduña, Andrés Cervantes, et al.. (2010). SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clinical & Translational Oncology. 12(11). 729–734.
20.
Broseta, Enrique, et al.. (1991). Unusual Foreign Bodies in the Urethra and Bladder. British Journal of Urology. 68(5). 510–512.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Olivier Dubreuil Breakdown of academic impact, for papers by Natsuko Okita Breakdown of academic impact, for papers by Takeru Wakatsuki Breakdown of academic impact, for papers by Lorenzo Antonuzzo Breakdown of academic impact, for papers by Usha Malhotra Breakdown of academic impact, for papers by Hironaga Satake Breakdown of academic impact, for papers by Boudewijn van Etten Breakdown of academic impact, for papers by Tomomichi Kiyomatsu Breakdown of academic impact, for papers by Hirokazu Shoji Breakdown of academic impact, for papers by G. Des Guetz